for us business update. our and quarter first afternoon, Good joining XXXX thank you for earnings and call
Medical Trevi's Officer. call Chief on reported Joining this are Clark, my Trevi's Lisa David me just Chief Officer; Financial earnings Delfini, We and QX ago. X Dr. today colleagues, weeks
cough then Lisa X answer cough as will So a advancing both I give pulmonary or and idiopathic .
This and chronic development questions. us a busy or to RCC brief happy as clinical IPF. update at Trevi, for our the well are time fibrosis is of plans any refractory
Refractory our is Let trials, later RCC, is me a the expected various to for trial and to X adult a XX% affects treatment beginning persistent of up condition. as with year. coffer the update a weeks out in brief greater Phase IIa debilitating than disease lasting which chronic despite population provide underlying read cough that defined RCC is on our this
mechanism differentiation the of any for therapies of The the for Haduvio action, lungs. need peripherally lack the in significant refractory works the of With brain unmet urgent which centrally point in continues for in U.S., cough RCC approved to in there and a synergistically therapies. the and is be new key both chronic potential
of effect PXXX mechanisms and has across to inhibitors. than peripheral the potentially stronger only a more baseline mechanism in counts potential patients We Haduvio's the cough believe a broader range like have work
IIa XX difference. run incorporate This IIa RIVER crossover trial trials randomized, [indiscernible] Phase the approximately is reduction to Our is X-period Phase does a date of design patients. meaningful similar RCC other in cough to placebo-controlled, a study, evaluating double-blind, but
with have will treatment those X-week Patients XX cough hour stratification separated be Each a a weeks per weekly titrated greater up will X twice change the cough with randomized dosing primary Haduvio from XX period. These and efficacy period to on those in XX last X:X by to dose is period. between endpoint hour. patients than per frequency washout by The XXX with the XX across the coughs an relative will milligrams measured daily as cough objective XX-hour milligrams monitor. the
measures an trial now subjects the XX The life. also outcome than to counts even for study and almost arm, greater of including study. all will secondary the XX and cough in and have see split the explore XX this in XX for activated We endpoints, quality each enrolled patient-reported cough sites between
to top year. of is line expect and second Enrollment progressing, we this the this data half in study continue from
role in a lead program IP. XX% on is approximately social IPF update suffering Next, factor also IPF that the plays our end-of-life an chronic patients have of a but may and disease disease. is significant of of and be in physical, underlying serious Chronic similar cough a RCC, psychological risk of that to impacts IPF the coughs. by progression reported from
for The worse hospitalization, outcomes health constant potential inflammation lung injury, caused patients such coughing as or by increased microtears may lead for mortality persistent and need to respiratory transplant.
therapies. With an have cough no need treatment and currently urgent approved providers chronic patients for IPF, and options new for
elevating of current shown therapies is most not one a programs in IPF, have an are cough, need. in-development aspects ongoing unmet of IPF and impact difficult of which on chronic there the While the lot development
Haduvio trial CORAL study active trial, is patients. is parallel arm X XXX Xb a of X-week approximately The and a will dose-ranging Our Phase that study in study placebo. doses
a timely in able to We complete to sites countries and study in this be multiple enrollment are conducting manner.
XX planned sites expect We our to the activated majority end of June. by the have of
progressing, for is guidance which study reaffirm study top are results is mind. of year, we for our to in half line of we the our Enrollment We our out continue the we size with this the ensure working half the to expect study sites and to first full this our analysis XXXX. top expect second in and sample from in read data reestimation of
assumptions, a will the results within SSRE complete, recommend the is intend utility. prespecified either range or a SSRE study As XX% indicate complete confirm is We share of subjects our reminder, it which the conducted the when once current study. to sizing upsizing
is we this made We half approximately also to progress potential and This XX% enrollment enrollment study now enrolled, good summer. complete our year. expect on study or have human abuse this
this of relative with and to upon by was the placebo designed to study butorfinol of objective FDA abuse parenteral is nalbuphine was agreed and Recall determine input. potential schedule that on the nalbuphine It's products is and X and and The are by or on recently left unscheduled rereviewed that also important parts Korsuva DEA as whether and schedule. as such Kappa be muoantagonists naltrexone. the it mechanism DEA agonist also to naloxone of nalbuphine's in such note oral the
our study includes work date the to preclinical an why as This unscheduled. drug done is rationale this mechanistic with of the submitted NDA part all be will for which X-factor plan,
health of public as HAP Our programs, clinical our data a results study well in generated development rationale. this the as
been nalbuphine form all has goal the years. ER is have remain oral unscheduled parental Our to these as
expect this We as line continue in from year study this the second half data top to well. of
patient U.S. by initiate the FDA, in we Finally, our our cough XXXX. physiology respiratory the IPF expect is goal nalbuphine and the levels was We study anticipate being and study this quarter of The in depression to varying study cleared of in to on third X of IND respiratory the for IPF disease U.K. severity conducted determine our population. and Phase measure this the ER in to impact of systematically
disorder the move want breathing we group characterize in in patients better To date, we forward. this studies, as excluded our have to sleep safety and we
path across believe chronic important the and from forward trials data As you Trevi, be will we development a Haduvio can conditions. inform busy see, for time for the cough it is these clinically to
to are this second the studies begin these We excited in reporting data. of and half completing the year
medical attending over San [indiscernible] European few Thoracic Cough in the management several Society Respiratory weeks, On London and including will Meeting Conference a Diego in next final of American conferences note, meeting July in a the Society September. couple our be the team months,
let for over know we financial if it attend then Please review would I love our to us you Lisa plan now questions. you. to it with to open results, as will up any meet turn we will to
